...
首页> 外文期刊>Human Pathology >Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases
【24h】

Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases

机译:血管浸润程度对低度囊性滤泡细胞源性甲状腺癌的预后影响:276例临床病理研究

获取原文
获取原文并翻译 | 示例

摘要

Continuous controversy surrounds the predictive value of the degree of vascular invasion (VI) in low-grade encapsulated follicular cell derived thyroid carcinomas (LGEFCs). Some guidelines advocate conservative therapy in LGEFCs with focal VI. There is therefore a need to assess the survival rates of LGEFC patients with various degrees of VI to better stratify patients for subsequent therapy. Furthermore, the prognostic effect of VI within the different histotypes of LGEFCs is not well known. A total of 276 patients with LGEFCs were subjected to a meticulous histopathologic analysis. They were classified as encapsulated papillary thyroid carcinoma, encapsulated follicular carcinoma (EFC), and encapsulated Hurthle cell carcinoma (EHCC). Of the 276 patients, 24 had extensive VI (EVI) (>= 4 foci) and 28 displayed focal (<4 foci) VI. EHCC and EFC showed a much higher rate of EVI than encapsulated papillary thyroid carcinoma. Median follow-up was 6 years. All 14 tumors with adverse behavior harbored distant metastases (DMs), of which 9 had DMs at presentation. All 3 patients without EVI who had aggressive carcinomas harbored DMs at presentation. EVI was an independent predictor of poor recurrence-free survival. Excluding cases with DMs at presentation, only patients with EVI had recurrence, and all relapsed cases were EHCC. EVI is an independent predictor of recurrence-free survival in LGEFCs. EHCC with EVI has a particularly high risk of recurrence. When DMs are not found at presentation, patients with focal VI are at a very low risk of recurrence even if not treated with radioactive iodine. (C) 2015 Elsevier Inc. All rights reserved.
机译:持续的争议围绕着低级囊状滤泡细胞源性甲状腺癌(LGEFC)的血管侵犯程度(VI)的预测价值。一些指南主张对局灶性VI进行LGEFCs保守治疗。因此,有必要评估具有不同程度VI的LGEFC患者的生存率,以更好地对患者进行分层以进行后续治疗。此外,VI在不同LGEFCs组织型中的预后效果尚不明确。总共276例LGEFCs患者接受了仔细的组织病理学分析。它们分为封装的甲状腺乳头状癌,封装的滤泡状癌(EFC)和封装的hurthle细胞癌(EHCC)。在276例患者中,有24例具有广泛的VI(EVI)(> = 4个灶),而28例显示了局灶性(<4灶)VI。与封装的甲状腺乳头状癌相比,EHCC和EFC的EVI率要高得多。中位随访时间为6年。具有不良行为的所有14例肿瘤均具有远处转移(DM),其中9例存在DM。所有3例没有EVI且患有侵袭性癌的患者在报告中均带有DM。 EVI是无复发生存率低的独立预测因子。不包括出现DM的病例,只有EVI患者复发,所有复发病例均为EHCC。 EVI是LGEFCs无复发生存的独立预测因子。带有EVI的EHCC复发风险特别高。当在就诊时未发现DM时,即使未接受放射性碘治疗,局灶性VI患者的复发风险也非常低。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号